Zenas BioPharma, Inc. - Common Stock (ZBIO)

CUSIP: 98937L105

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 7 signals
Share change
+5,733,672
Put/Call ratio
100%
SEC-reported price per share
$26.97
Indexed holders
108
Value change
+$155,517,307
Number of buys
63
Open additional details 1 more signal available
Number of sells
35
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
65,276,927

Security key

98937L105

Report period

Q3 2026

Indexed institutions

108

Top holders

10

Ownership snapshot

Top reported holders of ZBIO - Zenas BioPharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
10/15
Latest evidence
30 Sep 2026
13D/G 13F 3/4/5 Lead comparable stake: 14% 5 rows are not safely comparable across share classes. 13D/G row: FMR LLC Showing 1-6 of 15 holder rows.

Quick read

FMR LLC leads the comparable SEC ownership view at 14%.

10 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Comparable ownership Top 5
FMR LLC 14%
WELLINGTON MANAGEMENT GROUP LLP 12%
InnoCare Pharma Inc. 10%
SR ONE CAPITAL MANAGEMENT, LLC 7.7%
Moulder Leon O Jr. 5.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13D/G 13F
Company
14%
Reported 13D/G · 31 Dec 2025
$277,876,336
7,652,255 shares
+$109,228,632 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP
13D/G 13F
Company
12%
Reported 13D/G · 30 Sep 2026
$228,098,473
8,094,339 shares
+$43,064,817 30 Sep 2026
InnoCare Pharma Inc.
13D/G 3/4/5
10%+ Owner
10%
Reported 13D/G · 26 Aug 2026
$217,630,000
7,000,000 shares
+$62,180,000 26 Aug 2026
SR ONE CAPITAL MANAGEMENT, LLC
13D/G 3/4/5
10%+ Owner
7.7%
Reported 13D/G · 13 Aug 2026
$148,264,043
5,037,854 shares
$0 13 Aug 2026
Moulder Leon O Jr.
13D/G 3/4/5
Chief Executive Officer, Director
5.1%
Reported 13D/G · 29 Apr 2026
$67,767,315
3,220,880 shares
+$4,017,777 29 Apr 2026
BlackRock, Inc.
13D/G 13F
Company
5%
Reported 13D/G · 30 Sep 2026
$88,651,285
3,287,021 shares
$0 30 Sep 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
108
Shares
51,626,349
Indexed holders
108
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 indexed holders
143
Q3 2026 indexed holders
108
Indexed holder difference
-35
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .